BBOT vs. CANC

Last updated Apr 2, 2026

Compare and contrast key facts about BridgeBio Oncology Therapeutics, Inc (BBOT) and Tema Oncology ETF (CANC).

CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023.

Performance

BBOT vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Oncology Therapeutics, Inc (BBOT) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

BBOT vs. CANC - Yearly Performance Comparison

	2026 (YTD)	2025
BBOT BridgeBio Oncology Therapeutics, Inc	-27.88%	29.74%
CANC Tema Oncology ETF	6.91%	35.85%

Returns By Period

In the year-to-date period, BBOT achieves a -27.88% return, which is significantly lower than CANC's 6.91% return.

BBOT

• 1D: 0.89%
• 1M: -10.42%
• YTD: -27.88%
• 6M: -24.94%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CANC

• 1D: 1.16%
• 1M: -0.89%
• YTD: 6.91%
• 6M: 27.17%
• 1Y: 58.38%
• 3Y*: 140.92%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BBOT vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CANC

CANC Risk / Return Rank: 92
CANC Sharpe Ratio Rank: 92
CANC Sortino Ratio Rank: 92
CANC Omega Ratio Rank: 86
CANC Calmar Ratio Rank: 95
CANC Martin Ratio Rank: 94

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBOT vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Oncology Therapeutics, Inc (BBOT) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	BBOT	CANC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.17	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.13	-0.04	-0.10

Correlation

The correlation between BBOT and CANC is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BBOT vs. CANC - Dividend Comparison

BBOT has not paid dividends to shareholders, while CANC's dividend yield for the trailing twelve months is around 0.05%.

	TTM	2025	2024	2023
BBOT BridgeBio Oncology Therapeutics, Inc	0.00%	0.00%	0.00%	0.00%
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%

Drawdowns

BBOT vs. CANC - Drawdown Comparison

The maximum BBOT drawdown since its inception was -36.78%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for BBOT and CANC.

Drawdown Indicators

	BBOT	CANC	Difference
Max Drawdown Largest peak-to-trough decline	-36.78%	-97.53%	+60.75%
Max Drawdown (1Y) Largest decline over 1 year	—	-12.40%	—
Current Drawdown Current decline from peak	-34.23%	-55.68%	+21.45%
Average Drawdown Average peak-to-trough decline	-14.24%	-73.89%	+59.65%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.57%	—

Volatility

Volatility by Period

	BBOT	CANC	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	8.20%	—
Volatility (6M) Calculated over the trailing 6-month period	—	16.22%	—
Volatility (1Y) Calculated over the trailing 1-year period	75.21%	27.19%	+48.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	75.21%	285.53%	-210.32%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	75.21%	285.53%	-210.32%